277 related articles for article (PubMed ID: 8949645)
1. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Cuffari C; Théorêt Y; Latour S; Seidman G
Gut; 1996 Sep; 39(3):401-6. PubMed ID: 8949645
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche J; Desager JP; Horsmans Y; Louis E
Scand J Gastroenterol; 2001 Jan; 36(1):71-6. PubMed ID: 11218242
[TBL] [Abstract][Full Text] [Related]
3. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Cuffari C; Hunt S; Bayless T
Gut; 2001 May; 48(5):642-6. PubMed ID: 11302961
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy.
Cuffari C; Seidman EG; Latour S; Théorêt Y
Can J Physiol Pharmacol; 1996 May; 74(5):580-5. PubMed ID: 8884023
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
Dubinsky MC; Lamothe S; Yang HY; Targan SR; Sinnett D; Théorêt Y; Seidman EG
Gastroenterology; 2000 Apr; 118(4):705-13. PubMed ID: 10734022
[TBL] [Abstract][Full Text] [Related]
7. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Goldenberg BA; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
[TBL] [Abstract][Full Text] [Related]
8. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
[TBL] [Abstract][Full Text] [Related]
9. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
Gupta P; Gokhale R; Kirschner BS
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):450-4. PubMed ID: 11698762
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
11. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
12. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.
Mardini HE; Arnold GL
J Clin Gastroenterol; 2003; 36(5):390-5. PubMed ID: 12702978
[TBL] [Abstract][Full Text] [Related]
13. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Bonaz B; Boitard J; Marteau P; Lémann M; Coffin B; Flourié B; Belaiche J; Cadiot G; Metman EH; Cortot A; Colombel JF;
Aliment Pharmacol Ther; 2003 Aug; 18(4):401-8. PubMed ID: 12940925
[TBL] [Abstract][Full Text] [Related]
14. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
Cuffari C; Hunt S; Bayless TM
Aliment Pharmacol Ther; 2000 Aug; 14(8):1009-14. PubMed ID: 10930894
[TBL] [Abstract][Full Text] [Related]
15. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
[TBL] [Abstract][Full Text] [Related]
16. 6-MP metabolite levels: a potential guide to Crohn's disease therapy.
Sandborn WJ
Gastroenterology; 1997 Aug; 113(2):690-2. PubMed ID: 9247497
[No Abstract] [Full Text] [Related]
17. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Hanai H; Iida T; Takeuchi K; Arai O; Watanabe F; Abe J; Maruyama Y; Oohata A; Ikeya K; Kageoka M; Miwa I; Yoshirou S; Hosoda Y; Kubota T
Inflamm Bowel Dis; 2010 Aug; 16(8):1376-81. PubMed ID: 20049951
[TBL] [Abstract][Full Text] [Related]
18. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.
Dubinsky MC; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
Inflamm Bowel Dis; 2001 Aug; 7(3):181-9. PubMed ID: 11515842
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy.
Cuffari C; Li DY; Mahoney J; Barnes Y; Bayless TM
Dig Dis Sci; 2004 Jan; 49(1):133-7. PubMed ID: 14992447
[TBL] [Abstract][Full Text] [Related]
20. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.
Markowitz J; Grancher K; Kohn N; Lesser M; Daum F
Gastroenterology; 2000 Oct; 119(4):895-902. PubMed ID: 11040176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
